{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15","upperLimit":"33","value":"24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Responses assessed using computed tomography (CT) scans or magnetic resonance imaging according to standard Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria in order to assess disease progression. Complete Response (CR): Disappearance all target lesions; any pathological lymph nodes reduction in short axis to \\< 10 mm (\\< 1 cm). Partial Response (PR): \\> 30% decrease in sum diameters of target lesions. Progressive Disease (PD): \\> 20% increase in sum diameters lesions. (Note: appearance of one or \\> new lesions considered progressions). Stable Disease (SD): Neither shrinkage qualify for PR nor increase for PD.","dispersionType":"95% Confidence Interval","groups":[{"description":"This primary outcome measure is assessed from patients enrolled onto Part A of this study.","id":"OG000","title":"Part A: Nivolumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Response Rate: Number of Participants With Response (Part A)","type":"PRIMARY","unitOfMeasure":"percentage of patients with a response"}